Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
SINGAPORE, June 18, 2021 -- (Healthcare Sales & Marketing Network) -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. ... Biopharmaceuticals, Cardiology, Venture Capital Nuevocor, dilated cardiomyopathy, cardiomyopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Cardiomyopathy | Dilated Cardiomyopathy | Gene Therapy | Genetics | Heart | Marketing | Pharmaceuticals | Singapore Health | Venture Capital